---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-272860"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:43:27.168374+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beam reports BEAM-101 Phase 1/2 data: all 7 patients achieved >60% HbF, resolved anemia; ESCAPE proof-of-concept in NHPs

## Summary
- Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.
- Mean neutrophil engraftment 17.1 days, platelet 19.1 days; one death from busulfan-related respiratory failure deemed unrelated.
- ESCAPE antibody conditioning in NHPs enabled long-term engraftment of base-edited HSCs with >80% HbF-containing cells.
- BEAM-103 mAb dosing was well tolerated without transfusions or supportive care; minor declines in neutrophils/platelets.
- BEAM-302 initial clinical data from multiple cohorts now expected in first half of 2025.

## SEC filing metadata
- accession: 0001193125-24-272860
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/0001193125-24-272860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/d903914d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-272860
- JSON: https://secwatch.observer/filing/0001193125-24-272860.json
- Plain text: https://secwatch.observer/filing/0001193125-24-272860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.